BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 29954777)

  • 1. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.
    Pishvaian MJ; Bender RJ; Halverson D; Rahib L; Hendifar AE; Mikhail S; Chung V; Picozzi VJ; Sohal D; Blais EM; Mason K; Lyons EE; Matrisian LM; Brody JR; Madhavan S; Petricoin EF
    Clin Cancer Res; 2018 Oct; 24(20):5018-5027. PubMed ID: 29954777
    [No Abstract]   [Full Text] [Related]  

  • 2. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
    Pishvaian MJ; Blais EM; Brody JR; Lyons E; DeArbeloa P; Hendifar A; Mikhail S; Chung V; Sahai V; Sohal DPS; Bellakbira S; Thach D; Rahib L; Madhavan S; Matrisian LM; Petricoin EF
    Lancet Oncol; 2020 Apr; 21(4):508-518. PubMed ID: 32135080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
    Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
    Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.
    Lowery MA; Jordan EJ; Basturk O; Ptashkin RN; Zehir A; Berger MF; Leach T; Herbst B; Askan G; Maynard H; Glassman D; Covington C; Schultz N; Abou-Alfa GK; Harding JJ; Klimstra DS; Hechtman JF; Hyman DM; Allen PJ; Jarnagin WR; Balachandran VP; Varghese AM; Schattner MA; Yu KH; Saltz LB; Solit DB; Iacobuzio-Donahue CA; Leach SD; O'Reilly EM
    Clin Cancer Res; 2017 Oct; 23(20):6094-6100. PubMed ID: 28754816
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
    Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?
    Krepline AN; Bliss L; Geurts J; Akinola I; Christians KK; George B; Ritch PS; Hall WA; Erickson BA; Evans DB; Tsai S
    J Gastrointest Surg; 2020 Feb; 24(2):235-242. PubMed ID: 31745905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
    Ding D; Javed AA; Cunningham D; Teinor J; Wright M; Javed ZN; Wilt C; Parish L; Hodgin M; Ryan A; Judkins C; McIntyre K; Klein R; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Murphy A; Le DT; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; Manos L; Walsh C; Groshek L; Brown C; Yuan C; Blair AB; Groot V; Gemenetzis G; Yu J; Weiss MJ; Burkhart RA; Burns WR; He J; Cameron JL; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Hruban RH; Jaffee E; Wolfgang CL; Zheng L; Laheru DA
    Cancer Lett; 2021 Jan; 497():221-228. PubMed ID: 33127389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
    Lowder CY; Dhir T; Goetz AB; Thomsett HL; Bender J; Tatarian T; Madhavan S; Petricoin EF; Blais E; Lavu H; Winter JM; Posey J; Brody JR; Pishvaian MJ; Yeo CJ
    Surg Oncol; 2020 Jun; 33():118-125. PubMed ID: 32561076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 13. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer.
    Jung K; Lee S; Na HY; Kim JW; Lee JC; Hwang JH; Kim JW; Kim J
    Sci Rep; 2022 Dec; 12(1):20937. PubMed ID: 36463295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
    Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic testing for pancreatic cancer in clinical practice as real-world evidence.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okamura Y; Yanagita E; Matsuoka R; Amano T; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Pancreatology; 2018 Sep; 18(6):647-654. PubMed ID: 30055942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
    Aung KL; Fischer SE; Denroche RE; Jang GH; Dodd A; Creighton S; Southwood B; Liang SB; Chadwick D; Zhang A; O'Kane GM; Albaba H; Moura S; Grant RC; Miller JK; Mbabaali F; Pasternack D; Lungu IM; Bartlett JMS; Ghai S; Lemire M; Holter S; Connor AA; Moffitt RA; Yeh JJ; Timms L; Krzyzanowski PM; Dhani N; Hedley D; Notta F; Wilson JM; Moore MJ; Gallinger S; Knox JJ
    Clin Cancer Res; 2018 Mar; 24(6):1344-1354. PubMed ID: 29288237
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.
    San Lucas FA; Allenson K; Bernard V; Castillo J; Kim DU; Ellis K; Ehli EA; Davies GE; Petersen JL; Li D; Wolff R; Katz M; Varadhachary G; Wistuba I; Maitra A; Alvarez H
    Ann Oncol; 2016 Apr; 27(4):635-41. PubMed ID: 26681674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.